Quick Gain Fast Growth

[bassfishing101]

GNTA should rocked today with the news Genta Incorporated announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that tesetaxel, the latest addition to Genta's oncology product portfolio, has been granted designation as an "Orphan Drug" for treatment of patients with advanced gastric cancer. Orphan drug status provides for a period of marketing exclusivity, certain tax benefits, and an exemption from certain fees upon submission of a New Drug Application. As a late Phase 2 agent, the Company believes tesetaxel is the leading oral taxane currently in clinical development.